Drugs / Minoxidil
Minoxidil
also known as
Alopexil · Alostil · Loniten · Lonolox · Men's rogaine · Minodyl · Minoxidil (for men) · Minoxidil (for women) · +20 more
Small molecule targets AR via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | MEN'S ROGAINE | — | 2014-02-28 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | ROGAINE (FOR WOMEN) | — | 1991-08-13 – 1996-02-09 | fda.gov ↗ |
| Approved | US (FDA) | LONITEN | — | 1979-10-18 | fda.gov ↗ |
Trials 43
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05790941 | Mar → Jun 2023 | hypotrichosis | Aneira Pharma, Inc. | Unknown | No outcome recorded |
| Phase 0 | NCT05417308 | Mar 2023 → Dec 2027 expected | endocrine alopecia, female breast carcinoma | Ohio State University Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT03831334 | Apr 2019 → Jan 2024 overdue | chemotherapy-induced alopecia | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT07264790 | Mar 2026 → Sep 2027 expected | — | Duke University | Recruiting | No outcome recorded |
| Phase 1 | NCT06679556 | Nov → Dec 2024 | — | Samson Clinical Operations Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT07038941 | Mar → Jun 2024 | androgenetic alopecia | Beijing Dayspring Pharmaceutical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06015516 | Feb → Mar 2024 | — | Cantabria Labs | Completed | No outcome recorded |
| Phase 1 | NCT05864885 | Jun → Jul 2023 | androgenetic alopecia | Aneira Pharma, Inc. | Unknown | No outcome recorded |
| Phase 1/24 trials · 1 missed | ||||||
| Phase 1/2 | NCT06108193 | Jul → Dec 2023 | acne | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03488108 | Jan 2017 → May 2018 | alopecia | Mayo Clinic | Completed | Missed primary |
| Phase 1/2 | NCT01650272 | Jun 2012 → Feb 2013 | — | Siriraj Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT01643629 | Jan → Oct 2012 | androgenetic alopecia | Kasiak Research Pvt. Ltd. | Unknown | No outcome recorded |
| Phase 27 trials · 1 missed | ||||||
| Phase 2 | NCT07594678 | Nov 2026 → Dec 2027 expected | chemotherapy-induced alopecia, female breast carcinoma | Ohio State University Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07076706 | Dec 2024 → Aug 2025 | baldness, male pattern | Beijing Dayspring Pharmaceutical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05778825 | Mar 2023 → Mar 2027 expected | alopecia, childhood malignant neoplasm | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03852992 | Sep 2022 → Jul 2023 | baldness, male pattern | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT05272462 | Dec 2021 → Dec 2024 | ovarian carcinoma | Loyola University | Unknown | No outcome recorded |
| Phase 2 | NCT00876200 | Mar 2009 → Feb 2015 | Williams syndrome | Hospices Civils de Lyon | Completed | Missed primary |
| Phase 2 | NCT00175617 | Sep 2005 → Mar 2009 | androgenetic alopecia | University of British Columbia | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05990400 | May → Oct 2023 | androgenetic alopecia | Indonesia University | Unknown | No outcome recorded |
| Phase 312 trials · 2 met primary · 1 missed | ||||||
| Phase 3 | NCT07529977 | Jan 2027 → Oct 2028 expected | androgenetic alopecia | Eurofarma Laboratorios S.A. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07273799 | Dec 2025 → May 2026 overdue | androgenetic alopecia | Sheikh Zayed Federal Postgraduate Medical Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06924632 | Jul 2025 → May 2026 | baldness, male pattern | Samson Clinical Operations Pty Ltd | Completed | No outcome recorded |
| Phase 3 | NCT07080931 | Feb 2025 → Dec 2027 expected | androgenetic alopecia | Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05888922 | Oct 2024 → Oct 2026 expected | androgenetic alopecia | Cantabria Labs | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05989165 | Jun → Sep 2023 | androgenetic alopecia | Indonesia University | Completed | Met primary |
| Phase 3 | NCT04721548 | Mar 2023 → Mar 2024 | alopecia | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT03753113 | Nov 2018 → Sep 2019 | androgenetic alopecia | Farid Masoud | Completed | No outcome recorded |
| Phase 3 | NCT01391156 | Mar 2011 → Mar 2012 | androgenetic alopecia | Mae Fah Luang University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01226459 | Sep 2010 → Aug 2011 | androgenetic alopecia | Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. | Completed | Met primary |
| Phase 3 | NCT01145625 | Jun 2010 → Feb 2012 | alopecia | Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. | Completed | Missed primary |
| Phase 3 | NCT00151515 | Oct 2003 → Jul 2004 | androgenetic alopecia | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT06813963 | Feb 2025 → Feb 2026 | graying of hair, precocious | Southern Medical University, China | Completed | No outcome recorded |
| Phase 4 | NCT02283645 | Jan → Aug 2015 | — | Mae Fah Luang University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02275832 | Nov 2014 → Mar 2015 | — | Mae Fah Luang University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01924000 | Dec 2013 → Apr 2014 | Tented eyebrows, hypotrichosis | Mae Fah Luang University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01672307 | Sep → Nov 2012 | hypotrichosis | Mae Fah Luang University Hospital | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07563036 | Feb → Oct 2026 expected | androgenetic alopecia | Kasr El Aini Hospital | Recruiting | No outcome recorded |
| — | NCT07018349 | Jun → Sep 2025 overdue | androgenetic alopecia | Jinnah Postgraduate Medical Centre | Not yet recruiting | No outcome recorded |
| — | NCT06066827 | Aug → Nov 2023 | androgenetic alopecia | Dr. dr. Lili Legiawati, SpKK(K) | Unknown | No outcome recorded |
| — | NCT05369481 | Mar → Aug 2022 | androgenetic alopecia | Mohammed Abd El Mawgoud Amer | Unknown | No outcome recorded |
| — | NCT02460497 | May → Sep 2015 | androgenetic alopecia | Galderma R&D | Completed | No outcome recorded |
| — | NCT02460289 | May → Nov 2015 | androgenetic alopecia | Galderma R&D | Completed | No outcome recorded |
| Comparator or background therapy44 trials | ||||||
| Phase 0 | NCT07012486 Comparator | Jun 2025 → May 2026 overdue | androgenetic alopecia | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT06527729 Comparator | Jul 2021 → Jun 2022 | alopecia areata | Assiut University | Completed | No outcome recorded |
| Phase 1 | NCT02824380 Background | Jul → Oct 2016 | androgenetic alopecia | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT07203599 Comparator | Sep 2025 → Oct 2026 expected | androgenetic alopecia | Shenzhen People's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06333600 Comparator | May 2023 → Apr 2024 | androgenetic alopecia, skin disorder | Sohag University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05636904 Comparator | Dec 2022 → Mar 2024 | androgenetic alopecia | Dermaliq Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02280603 Comparator | Jan → Dec 2014 | androgenetic alopecia | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT07548918 Background | May 2026 → Feb 2027 expected | vitiligo | Sohag University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07370519 Comparator | Jan 2026 → Jan 2027 expected | androgenetic alopecia | Shenzhen People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07011485 Comparator | May → Aug 2025 overdue | androgenetic alopecia | PDFE Pharma Innovations FZCO | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06826001 Comparator | Feb → Jul 2025 overdue | androgenetic alopecia | Sheikh Zayed Medical College | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02279823 Comparator | Oct 2014 → Dec 2015 | androgenetic alopecia | Intrepid Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01900041 Background | Apr 2012 → May 2013 | androgenetic alopecia | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01325337 Comparator | Jun 2011 → Aug 2012 | baldness, male pattern | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01325350 Comparator | Jun 2011 → Jul 2012 | androgenetic alopecia | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01319370 Comparator | Nov 2010 → Mar 2013 | androgenetic alopecia | Natalie GARCIA BARTELS | Completed | No outcome recorded |
| Phase 2/3 | NCT04481412 Background | Jul 2020 → Nov 2021 | androgenetic alopecia | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT07435012 Comparator | Apr 2026 → Dec 2027 expected | androgenetic alopecia | Triple Hair Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT06501924 Comparator | Jan → Oct 2025 overdue | baldness, male pattern | Applied Biology, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06484881 Comparator | Sep → Oct 2024 | androgenetic alopecia | Applied Biology, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04594018 Comparator | Feb 2023 → May 2026 overdue | androgenetic alopecia | EMS | Recruiting | No outcome recorded |
| Phase 3 | NCT05296863 Background | Oct → Dec 2021 | androgenetic alopecia | Dr. dr. Lili Legiawati, SpKK(K) | Completed | No outcome recorded |
| Phase 3 | NCT01655108 Comparator | Mar 2012 → Oct 2013 | androgenetic alopecia | Brasilia University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00958750 Comparator | Jun 2008 → Feb 2009 | androgenetic alopecia | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT07518342 Comparator | Apr 2026 → Jun 2028 expected | androgenetic alopecia | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07459933 Comparator | Mar → Sep 2026 overdue | alopecia areata | Jinnah Postgraduate Medical Centre | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06043349 Comparator | Jun → Sep 2023 | androgenetic alopecia | Indonesia University | Unknown | No outcome recorded |
| Phase 4 | NCT04293822 Comparator | Jun → Nov 2020 | androgenetic alopecia | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT04209803 Comparator | Dec 2018 → Sep 2020 | androgenetic alopecia | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT04207931 Comparator | Apr 2018 → Nov 2026 expected | central centrifugal cicatricial alopecia | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT02483195 Comparator | Aug 2016 → Aug 2018 | androgenetic alopecia | University of Florida | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT03535233 Comparator | Mar 2016 → Jun 2017 | alopecia areata | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT04090801 Comparator | May 2015 → May 2016 | androgenetic alopecia | Sohag University | Completed | No outcome recorded |
| — | NCT07536100 Comparator | May → Nov 2026 expected | androgenetic alopecia | Institute of Dermatology, Thailand | Recruiting | No outcome recorded |
| — | NCT07502976 Comparator | Jan → Oct 2026 expected | androgenetic alopecia | Kasr El Aini Hospital | Recruiting | No outcome recorded |
| — | NCT07373054 Comparator | Nov 2025 → Jul 2026 | androgenetic alopecia | Fujian Medical University Union Hospital | Completed | No outcome recorded |
| — | NCT06218394 Comparator | Dec 2023 → Sep 2024 | androgenetic alopecia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT06218498 Comparator | Nov 2023 → Jun 2024 | androgenetic alopecia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05587257 Comparator | Jan 2023 → Jan 2024 | alopecia areata | Assiut University | Unknown | No outcome recorded |
| — | NCT05827991 Comparator | Mar 2022 → Dec 2023 | androgenetic alopecia | Xijing Hospital | Unknown | No outcome recorded |
| — | NCT03528772 Comparator | May 2018 → Aug 2019 | — | Mansoura University | Completed | No outcome recorded |
| — | NCT02486848 Comparator | Jun → Dec 2016 | androgenetic alopecia | Maja Kovacevic, MD | Withdrawn | No outcome recorded |
| — | NCT00607477 Comparator | Jan 2008 → Jan 2009 | hypertensive disorder | University of Chicago | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-04-13 | Aytu BioPharma, Inc. | Aytu BioScience Consumer Health Subsidiary Launches Regoxidine(R), an FDA Approved Hair Regrowth Treatment Foam that Contains 5% Minoxidil and Targets Over 11 Million U.S. Consumers Who Purchased Hair Regrowth Products in 2019 aytubio.com ↗ |
| 2017-03-08 | Perrigo Company | Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine® Foam perrigo.com ↗ |
| 2012-03-01 | Perrigo Company | Perrigo Announces the First Store Brand Launch of the Generic Version of Rogaine® 5% Foam perrigo.com ↗ |
| 2011-05-02 | Perrigo Company | Perrigo Announces FDA Final Approval for Minoxidil Foam - Generic Equivalent to Men's Rogaine® Foam perrigo.com ↗ |
| 2011-02-10 | Perrigo Company | Perrigo Announces Settlement of Rogaine® Foam Patent Litigation perrigo.com ↗ |
| 2009-10-13 | Perrigo Company | Perrigo Confirms Filing for Generic Version of Men's Rogaine® Foam perrigo.com ↗ |
Evidence & citations 33 cited values
Every value below carries the sentence it was read from. 88 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Minoxidil | “This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.” NCT00175617 ↗86“combination of minoxidil and finasteride” NCT07038941 ↗ “5% minoxidil / high dose of finasteride” NCT02824380 ↗ “guanfacine, hydralazine, minoxidil” NCT00684489 ↗ “2 % Minoxidil and /or Finasteride” NCT01643629 ↗ |
| Known as | Alopexil | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Alostil | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Loniten | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Lonolox | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Men's rogaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Minodyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Minoxidil (for men) | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Minoxidil (for women) | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Minoxidil extra strength (for men) | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Minoxidil Forte | “Minoxidil Forte 5% topical gel 60 gm; Pharmacare Egypt Co., Cairo, Egypt” NCT03528772 ↗ |
| Known as | Minoximen | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Mintop | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Normoxidil | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | NSC-757106 | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Pierminox | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Prexidil | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Regaine for men | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Regaine for women | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Regaxidil | “The reference drug is minoxidil 20 mg/ml (2%) topical solution, marketed in Spain by Industrial Farmacéutica Cantabria, S.A., under the name the trade name of Regaxidil®.” NCT06015516 ↗ |
| Known as | Riup | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Rogaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Rogaine (for men) | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Rogaine (for women) | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Rogaine extra strength (for men) | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Theroxidil | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Tricoxidil | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | U-10,858 | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Known as | Women's rogaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL802 ↗ |
| Action | Activate | “as a pharmacological agent capable to stimulate elastin expression” NCT00876200 ↗ |
| Modality | Small molecule | — CHEMBL802 ↗ |
| Route | Topical | “Topical 5% minoxidil foam formulation used twice daily” NCT00151515 ↗ |
| Target | AR | “The previous study showed minoxidil could reduce AR expression in messenger ribonucleic acid (mRNA) and protein level in Human Hair Dermal Papilla Cells (HHDPCs).” NCT06108193 ↗ |